Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian M McElree

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Urology Practice|December 2, 2025
Editorial CommentaryIan M McElree, Cameron J Britton
Urology|May 21, 2023
EDITORIAL COMMENTMadison M Wahlen, Ian M McElree, Vignesh T Packiam
The Journal of Urology|February 26, 2026
Editorial CommentRandie E White, Ian M McElree, Jeffrey J Tosoian
BJU International|January 19, 2026
Impact of American Urological Association risk category on outcomes of intravesical BCG vs gemcitabine/docetaxel in high-grade Ta non-muscle-invasive bladder cancerMohamad Abou Chakra, Ian M McElree, Sarah L Mott, et al.
BJU International|October 20, 2023
Alternative instillation techniques of sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancerIan M McElree, Sarah L Mott, Michael A O'Donnell, et al.
Urology Case Reports|August 21, 2023
Recurrent heterotopic ossification following open radical nephrectomyJordan R Richards, Ian M McElree, Joanna Orzel, et al.
Cureus|April 5, 2024
Management of Renal Cell Carcinoma With Supradiaphragmatic Inferior Vena Cava Thrombus Diagnosed During Acute COVID-19 InfectionMichael Leyderman, Ian M McElree, Kenneth G Nepple, et al.
Urologic Oncology|November 26, 2024
The efficacy of sequential intravesical gemcitabine and docetaxel versus BCG for the treatment of European association of urology very-high risk non-muscle invasive bladder cancerMohamad Abou Chakra, Vignesh T Packiam, Ian M McElree, et al.
Urologic Oncology|May 25, 2024
Early experience with sequential intravesical gemcitabine and docetaxel for micropapillary variant non-muscle invasive bladder cancerMohamad Abou Chakra, Ian M McElree, Vignesh T Packiam, et al.
JAMA Network Open|February 28, 2023
Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non-Muscle-Invasive Bladder CancerIan M McElree, Ryan L Steinberg, Sarah L Mott, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Urology Practice|December 2, 2025
Editorial CommentaryIan M McElree, Cameron J Britton
Urology|May 21, 2023
EDITORIAL COMMENTMadison M Wahlen, Ian M McElree, Vignesh T Packiam
The Journal of Urology|February 26, 2026
Editorial CommentRandie E White, Ian M McElree, Jeffrey J Tosoian
BJU International|January 19, 2026
Impact of American Urological Association risk category on outcomes of intravesical BCG vs gemcitabine/docetaxel in high-grade Ta non-muscle-invasive bladder cancerMohamad Abou Chakra, Ian M McElree, Sarah L Mott, et al.
BJU International|October 20, 2023
Alternative instillation techniques of sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancerIan M McElree, Sarah L Mott, Michael A O'Donnell, et al.
Urology Case Reports|August 21, 2023
Recurrent heterotopic ossification following open radical nephrectomyJordan R Richards, Ian M McElree, Joanna Orzel, et al.
Cureus|April 5, 2024
Management of Renal Cell Carcinoma With Supradiaphragmatic Inferior Vena Cava Thrombus Diagnosed During Acute COVID-19 InfectionMichael Leyderman, Ian M McElree, Kenneth G Nepple, et al.
Urologic Oncology|November 26, 2024
The efficacy of sequential intravesical gemcitabine and docetaxel versus BCG for the treatment of European association of urology very-high risk non-muscle invasive bladder cancerMohamad Abou Chakra, Vignesh T Packiam, Ian M McElree, et al.
Urologic Oncology|May 25, 2024
Early experience with sequential intravesical gemcitabine and docetaxel for micropapillary variant non-muscle invasive bladder cancerMohamad Abou Chakra, Ian M McElree, Vignesh T Packiam, et al.
JAMA Network Open|February 28, 2023
Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non-Muscle-Invasive Bladder CancerIan M McElree, Ryan L Steinberg, Sarah L Mott, et al.
Pageof 3